The treatment of hepatic encephalopathy

被引：0
作者：
Marsha Y. Morgan
A. Blei
K. Grüngreiff
R. Jalan
G. Kircheis
G. Marchesini
O. Riggio
Karin Weissenborn
机构：
[1] Royal Free Campus,Centre for Hepatology, Division of Medicine
[2] Royal Free and University College Medical School,Institute of Hepatology, Division of Medicine
[3] University College London,Department of Gastroenterology, Hepatology and Infectiology
[4] Northwestern University,Unit of Clinical Dietetics
[5] Hepatology Outpatient Practice,Department of Clinical Medicine, Division of Gastroenterology
[6] Bloomsburg Campus,Department of Neurology
[7] Royal Free and University College Medical School,undefined
[8] University College London,undefined
[9] Heinrich-Heine-University,undefined
[10] Alma Mater Studiorum University,undefined
[11] University of Rome La Sapienza,undefined
[12] Medical School Hannover,undefined
来源：
Metabolic Brain Disease | 2007年 / 22卷
关键词：
Branched-chain amino acids; Bromocriptine; Hepatic cirrhosis; Hepatic encephalopathy; Non-absorbable antibiotics; Non-absorbable disaccharides; Ornithine aspartate; Sodium benzoate; Treatment; Zinc;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.
引用
收藏
页码：389 / 405
页数：16
相关论文
共 306 条
[1]  
Als-Nielsen B(2004)Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials BMJ 328 1046-1051
[2]  
Gluud LL(2006)The current pharmacological therapies for hepatic encephalopathy Aliment Pharmacol Ther 25 23-31
[3]  
Gluud C(1966)Treatment of chronic portal systemic encephalopathy with lactulose Lancet i 890-892
[4]  
Bass NM(1994)Lactulose–neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial Gastroenterol Clin Biol 18 1063-1068
[5]  
Bircher J(2004)Infection, inflammation and hepatic encephalopathy, synergism redefined J Hepatol 40 327-330
[6]  
Müller J(2003)Chronic hyperammonemia alters motor and neurochemical responses to activation of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo Neurobiol Dis 14 380-390
[7]  
Guggenheim P(1994)Zinc and immunity Nutrition 10 79-80
[8]  
Hammerli UP(2005)Treatment of hepatic encephalopathy Lancet 365 1384-1385
[9]  
Blanc P(1993)Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat J Clin Invest 92 2834-2840
[10]  
Daures JP(2005)Oral administration of sidenafil restore learning ability in rats with hyperammonemia and with portacaval shunts Hepatology 41 299-306
12345678910